Anticancer treatment of endostatin gene therapy by targeting tumor neovasculature in C57/BL mice

Article type: Research Article

Authors: Jia, Shidong^{; ;} | Zhu, Fuxiang | Li, Hongwei | He, Fuchu | Xiu, Ruijuan

Affiliations: Institute of Microcirculation, Chinese Academy of Medical Sciences & Peking Union Medical College, 5 Dung, Dan San Tiao, Beijing 100005, China | Beijing Institute of Radiation Medicine, Chinese National Human Genome Center at Beijing, 27 Taiping Road, Beijing 100850, China

Note: [] Corresponding author. Fax: +86 10 6201 5012; E‐mail: xiurj@cdm.imicam.ac.cn.

Abstract: Antiangiogenesis strategy has been widely recognized as a viable approach to fight cancer. Considering the high cost and inconvenience of protein therapy of endostatin (ES), which is a potent antiangiogenic protein, we attempted to explore the inhibitory effect of ES gene therapy on tumor growth and metastasis. In this experiment, Lewis lung carcinoma (LLC)‐bearing C57/BL mice were used to evaluate the antitumor effect of ES gene therapy and its impairment of tumor neovasculature. The data showed that the ectopic ES in circulation expressed by intramuscular administration of formulated ES‐encoding plasmid DNA significantly suppressed primary tumor growth and lung metastasis in LLC‐bearing C57/BL mice. Hence, our results demonstrated the inhibitory effect of ES gene therapy on angiogenesis‐dependent tumor growth and metastasis.

Keywords: Tumor, angiogenesis, endostatin, gene therapy

Journal: Clinical Hemorheology and Microcirculation, vol. 23, no. 2,3,4, pp. 251-257, 2000